CFLAR: A Potential Drug Target and Biomarker for Apoptosis Regulatory Network in Cancer

Target Name: CFLAR

NCBI ID: G8837

CFLAR

CFLAR: A Potential Drug Target and Biomarker for Apoptosis Regulatory Network in Cancer

Abstract:

CFLAR (CASP8 and FADD-like apoptosis regulator) is a non-coding RNA molecule that plays a crucial role in the regulation of apoptosis (programmed cell death) in cancer cells. CFLAR has been shown to be involved in the inhibition of cell survival and the promotion of cell apoptosis, thereby contributing to the development and progression of cancer. This article aims to provide an overview of CFLAR, its function in cancer, and its potential as a drug target or biomarker.

Introduction:

Apoptosis is a critical mechanism of cell death, which is tightly regulated to maintain tissue homeostasis and prevent pathological cell growth. During cancer development, aberrant apoptosis has been observed, leading to the formation of cancer stem cells and the development of a more aggressive disease. Therefore, the regulation of apoptosis is a prime target for cancer therapies.

CFLAR, a non-coding RNA molecule, has been identified as a key regulator of apoptosis in cancer cells. CFLAR plays a crucial role in the inhibition of cell survival and the promotion of cell apoptosis.

Function of CFLAR:

CFLAR is a small non-coding RNA molecule that is expressed in various tissues and cells, including cancer cells. It has been shown to be involved in the regulation of apoptosis by inhibiting the activities of several apoptosis-related proteins, including caspases.

CFLAR functions as an inhibitor of caspase-3, which is a key executor of cell apoptosis. By inhibiting caspase-3, CFLAR prevents the release of pro-inflammatory cytokines and limits the damage caused by apoptosis-related events.

Additionally, CFLAR has been shown to promote the formation of apoptosis-resistance cells by inhibiting the activities of DNA-binding proteins, which are crucial for the execution of apoptosis.

Potential as a Drug Target:

CFLAR's ability to regulate apoptosis makes it an attractive drug target for cancer therapies. By inhibiting the activities of caspases and promoting apoptosis, CFLAR can be used to treat cancer by triggering apoptosis in cancer cells.

CFLAR has been shown to be involved in the regulation of cell survival and the promotion of cell apoptosis, which can be useful in targeting cancer cells with specific therapeutic strategies. For example, CFLAR has been shown to be involved in the regulation of cancer cell apoptosis in response to chemotherapy, which could be a promising target for cancer chemotherapy.

Potential as a Biomarker:

CFLAR has also been shown to be a potential biomarker for cancer. Its expression level has been shown to be regulated by various factors, including cancer status, treatment, and environmental factors. Therefore, CFLAR could be used as a biomarker for cancer diagnosis, monitoring, and response to therapy.

Conclusion:

CFLAR is a non-coding RNA molecule that plays a crucial role in the regulation of apoptosis in cancer cells. Its function as an inhibitor of caspase-3 and promoteor apoptosis makes it an attractive drug target and biomarker for cancer therapies. Further studies are needed to fully understand the role of CFLAR in cancer and its potential as a drug target and biomarker.

Protein Name: CASP8 And FADD Like Apoptosis Regulator

Functions: Apoptosis regulator protein which may function as a crucial link between cell survival and cell death pathways in mammalian cells. Acts as an inhibitor of TNFRSF6 mediated apoptosis. A proteolytic fragment (p43) is likely retained in the death-inducing signaling complex (DISC) thereby blocking further recruitment and processing of caspase-8 at the complex. Full length and shorter isoforms have been shown either to induce apoptosis or to reduce TNFRSF-triggered apoptosis. Lacks enzymatic (caspase) activity

The "CFLAR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFLAR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets